Clinical trialNo phase (not a drug trial)Active not recruiting
An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma
Machine Learning Approach to Sonographic Assessment of Tumor Volumes for Response Assessment in Patients With Pancreas or Gastrointestinal Adenocarcinoma: A Pilot Study
- Outcome
- Ongoing
- Phase
- No phase (not a drug trial)
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 6 April 2021
- Expected end
- 6 April 2027
- Enrollment
- 19 participants
- Sites
- 1
- Primary outcomes
- measurement differences between ultrasound tumor volumes
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 27 April 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to see if ultrasound images that are analyzed by a special computer program can be used to measure the size of PDAC tumors in the liver as accurately as CT scans that involve contrast material (also called contrast-enhanced CT scans). All participants in this study will have pancreatic ductal adenocarcinoma (PDAC) that has spread (metastasized) to the liver, and all participants will be scheduled for a routine CT scan that will measure their cancer.